The potential shared role of inflammation in insulin resistance and schizophrenia: A bidirectional two-sample mendelian randomization study.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
03 2021
Historique:
received: 07 11 2019
accepted: 26 10 2020
entrez: 12 3 2021
pubmed: 13 3 2021
medline: 23 7 2021
Statut: epublish

Résumé

Insulin resistance predisposes to cardiometabolic disorders, which are commonly comorbid with schizophrenia and are key contributors to the significant excess mortality in schizophrenia. Mechanisms for the comorbidity remain unclear, but observational studies have implicated inflammation in both schizophrenia and cardiometabolic disorders separately. We aimed to examine whether there is genetic evidence that insulin resistance and 7 related cardiometabolic traits may be causally associated with schizophrenia, and whether evidence supports inflammation as a common mechanism for cardiometabolic disorders and schizophrenia. We used summary data from genome-wide association studies of mostly European adults from large consortia (Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) featuring up to 108,557 participants; Diabetes Genetics Replication And Meta-analysis (DIAGRAM) featuring up to 435,387 participants; Global Lipids Genetics Consortium (GLGC) featuring up to 173,082 participants; Genetic Investigation of Anthropometric Traits (GIANT) featuring up to 339,224 participants; Psychiatric Genomics Consortium (PGC) featuring up to 105,318 participants; and Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium featuring up to 204,402 participants). We conducted two-sample uni- and multivariable mendelian randomization (MR) analysis to test whether (i) 10 cardiometabolic traits (fasting insulin, high-density lipoprotein and triglycerides representing an insulin resistance phenotype, and 7 related cardiometabolic traits: low-density lipoprotein, fasting plasma glucose, glycated haemoglobin, leptin, body mass index, glucose tolerance, and type 2 diabetes) could be causally associated with schizophrenia; and (ii) inflammation could be a shared mechanism for these phenotypes. We conducted a detailed set of sensitivity analyses to test the assumptions for a valid MR analysis. We did not find statistically significant evidence in support of a causal relationship between cardiometabolic traits and schizophrenia, or vice versa. However, we report that a genetically predicted inflammation-related insulin resistance phenotype (raised fasting insulin (raised fasting insulin (Wald ratio OR = 2.95, 95% C.I, 1.38-6.34, Holm-Bonferroni corrected p-value (p) = 0.035) and lower high-density lipoprotein (Wald ratio OR = 0.55, 95% C.I., 0.36-0.84; p = 0.035)) was associated with schizophrenia. Evidence for these associations attenuated to the null in multivariable MR analyses after adjusting for C-reactive protein, an archetypal inflammatory marker: (fasting insulin Wald ratio OR = 1.02, 95% C.I, 0.37-2.78, p = 0.975), high-density lipoprotein (Wald ratio OR = 1.00, 95% C.I., 0.85-1.16; p = 0.849), suggesting that the associations could be fully explained by inflammation. One potential limitation of the study is that the full range of gene products from the genetic variants we used as proxies for the exposures is unknown, and so we are unable to comment on potential biological mechanisms of association other than inflammation, which may also be relevant. Our findings support a role for inflammation as a common cause for insulin resistance and schizophrenia, which may at least partly explain why the traits commonly co-occur in clinical practice. Inflammation and immune pathways may represent novel therapeutic targets for the prevention or treatment of schizophrenia and comorbid insulin resistance. Future work is needed to understand how inflammation may contribute to the risk of schizophrenia and insulin resistance.

Sections du résumé

BACKGROUND
Insulin resistance predisposes to cardiometabolic disorders, which are commonly comorbid with schizophrenia and are key contributors to the significant excess mortality in schizophrenia. Mechanisms for the comorbidity remain unclear, but observational studies have implicated inflammation in both schizophrenia and cardiometabolic disorders separately. We aimed to examine whether there is genetic evidence that insulin resistance and 7 related cardiometabolic traits may be causally associated with schizophrenia, and whether evidence supports inflammation as a common mechanism for cardiometabolic disorders and schizophrenia.
METHODS AND FINDINGS
We used summary data from genome-wide association studies of mostly European adults from large consortia (Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) featuring up to 108,557 participants; Diabetes Genetics Replication And Meta-analysis (DIAGRAM) featuring up to 435,387 participants; Global Lipids Genetics Consortium (GLGC) featuring up to 173,082 participants; Genetic Investigation of Anthropometric Traits (GIANT) featuring up to 339,224 participants; Psychiatric Genomics Consortium (PGC) featuring up to 105,318 participants; and Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium featuring up to 204,402 participants). We conducted two-sample uni- and multivariable mendelian randomization (MR) analysis to test whether (i) 10 cardiometabolic traits (fasting insulin, high-density lipoprotein and triglycerides representing an insulin resistance phenotype, and 7 related cardiometabolic traits: low-density lipoprotein, fasting plasma glucose, glycated haemoglobin, leptin, body mass index, glucose tolerance, and type 2 diabetes) could be causally associated with schizophrenia; and (ii) inflammation could be a shared mechanism for these phenotypes. We conducted a detailed set of sensitivity analyses to test the assumptions for a valid MR analysis. We did not find statistically significant evidence in support of a causal relationship between cardiometabolic traits and schizophrenia, or vice versa. However, we report that a genetically predicted inflammation-related insulin resistance phenotype (raised fasting insulin (raised fasting insulin (Wald ratio OR = 2.95, 95% C.I, 1.38-6.34, Holm-Bonferroni corrected p-value (p) = 0.035) and lower high-density lipoprotein (Wald ratio OR = 0.55, 95% C.I., 0.36-0.84; p = 0.035)) was associated with schizophrenia. Evidence for these associations attenuated to the null in multivariable MR analyses after adjusting for C-reactive protein, an archetypal inflammatory marker: (fasting insulin Wald ratio OR = 1.02, 95% C.I, 0.37-2.78, p = 0.975), high-density lipoprotein (Wald ratio OR = 1.00, 95% C.I., 0.85-1.16; p = 0.849), suggesting that the associations could be fully explained by inflammation. One potential limitation of the study is that the full range of gene products from the genetic variants we used as proxies for the exposures is unknown, and so we are unable to comment on potential biological mechanisms of association other than inflammation, which may also be relevant.
CONCLUSIONS
Our findings support a role for inflammation as a common cause for insulin resistance and schizophrenia, which may at least partly explain why the traits commonly co-occur in clinical practice. Inflammation and immune pathways may represent novel therapeutic targets for the prevention or treatment of schizophrenia and comorbid insulin resistance. Future work is needed to understand how inflammation may contribute to the risk of schizophrenia and insulin resistance.

Identifiants

pubmed: 33711016
doi: 10.1371/journal.pmed.1003455
pii: PMEDICINE-D-19-04114
pmc: PMC7954314
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1003455

Subventions

Organisme : Wellcome Trust
ID : 204623/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00006/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 201486/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12015/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L010305/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00006/2
Pays : United Kingdom
Organisme : Department of Health
ID : DRF-2018-11-ST2-018
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00002/7
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S037675/1
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/18/13/33946
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH/12/2/29428
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_17213
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/13/13/30194
Pays : United Kingdom
Organisme : Department of Health
ID : RP-PG- 0616-20003
Pays : United Kingdom
Organisme : Department of Health
ID : 127700
Pays : United Kingdom

Déclaration de conflit d'intérêts

We have read the journal's policy and the authors of this manuscript have the following competing interests. SB is a paid statistical consultant on PLOS Medicine's statistical board. CL is an Academic Editor on PLOS Medicine's editorial board. PBJ has received honoraria for providing scientific advice to Jansen, Ricordati and Lundbeck.

Références

PLoS Med. 2005 May;2(5):e151; quiz e175
pubmed: 15916460
Int J Epidemiol. 2020 Jun 1;49(3):1057
pubmed: 32529219
Br J Psychiatry. 2003 Dec;183:534-9
pubmed: 14645025
Am J Epidemiol. 2015 Feb 15;181(4):251-60
pubmed: 25632051
JAMA Psychiatry. 2017 Dec 1;74(12):1226-1233
pubmed: 29094161
Schizophr Bull. 2018 Oct 17;44(6):1195-1203
pubmed: 29762765
Nat Genet. 2017 Jan;49(1):17-26
pubmed: 27841877
Contrib Nephrol. 2006;151:151-164
pubmed: 16929139
Schizophr Res. 2014 May;155(1-3):101-8
pubmed: 24704219
Arch Gen Psychiatry. 2007 Oct;64(10):1123-31
pubmed: 17909124
Lancet. 2016 Jul 2;388(10039):86-97
pubmed: 26777917
Perspect Psychol Sci. 2010 Sep;5(5):527-45
pubmed: 26162196
Int J Epidemiol. 2015 Feb;44(1):108-16
pubmed: 25501686
Schizophr Bull. 2019 Mar 7;45(2):330-338
pubmed: 29635418
Trends Immunol. 2004 Jan;25(1):4-7
pubmed: 14698276
Brain Behav Immun. 2018 Mar;69:264-272
pubmed: 29197507
EBioMedicine. 2018 Aug;34:182-188
pubmed: 30100396
BMC Endocr Disord. 2015 Mar 02;15:9
pubmed: 25887236
Psychol Med. 2019 Oct;49(14):2307-2319
pubmed: 31439071
Schizophr Res. 2018 May;195:286-289
pubmed: 29092750
PLoS Med. 2007 Oct 16;4(10):e296
pubmed: 17941714
Mol Psychiatry. 2016 Apr;21(4):554-64
pubmed: 26169974
JAMA Psychiatry. 2017 Mar 1;74(3):261-269
pubmed: 28097367
Ann Gen Psychiatry. 2017 Feb 15;16:12
pubmed: 28289436
Nat Genet. 2015 Nov;47(11):1236-41
pubmed: 26414676
Clin Psychopharmacol Neurosci. 2014 Dec;12(3):209-14
pubmed: 25598824
Lancet Psychiatry. 2017 Jul;4(7):e14
pubmed: 28652047
Bipolar Disord. 2014 May;16(3):277-88
pubmed: 24330321
Lancet. 2013 Sep 14;382(9896):951-62
pubmed: 23810019
Curr Opin Clin Nutr Metab Care. 2016 Nov;19(6):408-417
pubmed: 27552473
Sci Rep. 2017 Jan 06;7:40055
pubmed: 28059134
Vitam Horm. 2009;80:613-33
pubmed: 19251052
Am J Hum Genet. 2018 Nov 1;103(5):691-706
pubmed: 30388399
JAMA Psychiatry. 2014 Oct;71(10):1121-8
pubmed: 25133871
Nat Genet. 2018 May;50(5):693-698
pubmed: 29686387
Ann Behav Med. 2012 Dec;44(3):399-407
pubmed: 22865468
Brain Behav Immun. 2017 Jan;59:253-259
pubmed: 27622678
Obes Res Clin Pract. 2019 Mar - Apr;13(2):214-216
pubmed: 30826255
Nat Genet. 2018 Mar;50(3):381-389
pubmed: 29483656
Bioinformatics. 2016 Oct 15;32(20):3207-3209
pubmed: 27318201
Am J Hum Genet. 2017 Nov 2;101(5):737-751
pubmed: 29100087
Wellcome Open Res. 2019 Nov 26;4:186
pubmed: 32760811
FASEB J. 1999 Dec;13(15):2173-8
pubmed: 10593864
Int J Epidemiol. 2016 Dec 1;45(6):1961-1974
pubmed: 27616674
Maturitas. 2011 May;69(1):41-9
pubmed: 21466928
Br J Psychiatry. 2017 Dec;211(6):339-349
pubmed: 28982658
Schizophr Bull. 2013 Mar;39(2):306-18
pubmed: 22207632
Schizophr Res. 2019 Apr;206:4-12
pubmed: 30573407
J Investig Med. 2009 Dec;57(8):874-81
pubmed: 19809367
Psychoneuroendocrinology. 2016 Jan;63:144-54
pubmed: 26444588
Bioinformatics. 2015 Nov 1;31(21):3555-7
pubmed: 26139635
Hum Mol Genet. 2018 Aug 1;27(R2):R195-R208
pubmed: 29771313
Stat Med. 2015 Feb 10;34(3):454-68
pubmed: 25382280
Obes Res. 2003 Apr;11(4):525-31
pubmed: 12690081
Lancet Psychiatry. 2016 Nov;3(11):1049-1058
pubmed: 27720402

Auteurs

Benjamin I Perry (BI)

Department of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, England.
Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, England.

Stephen Burgess (S)

MRC Biostatistics Unit, University of Cambridge, Cambridge, England.

Hannah J Jones (HJ)

NIHR Biomedical Research Centre, University Hospitals Bristol NHS Foundation Trust and University of Bristol, Bristol, United Kingdom.
Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England.

Stan Zammit (S)

NIHR Biomedical Research Centre, University Hospitals Bristol NHS Foundation Trust and University of Bristol, Bristol, United Kingdom.
Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England.
MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, Wales.

Rachel Upthegrove (R)

Institute for Mental Health, University of Birmingham, Birmingham, England.

Amy M Mason (AM)

Department of Public Health and Primary Care, University of Cambridge, Cambridge, England.

Felix R Day (FR)

MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, England.

Claudia Langenberg (C)

MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, England.

Nicholas J Wareham (NJ)

MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, England.

Peter B Jones (PB)

Department of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, England.
Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, England.

Golam M Khandaker (GM)

Department of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, England.
Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, England.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH